Table 1.

Case series of adjuvant radiation including node-positive patients.

Paper	N	Node-Positive (%)	SLNB Performed (%)	Radiation			Median Follow-Up	Recurrence Endpoints
				Adjuvant	Definitive	Total N (%)		Reported Endpoint by Stage	I	II	III a	III b	Total
Santamaria-Barria et al. [6]	161	32%	17.0%	79	0	79 (49%)	36 months	Recurrence rate (%)	34	50	47	68	44
Harrington et al. [7]	179	23%	3.4%	95	37	132 (74%)	48 months	Locoregional recurrence (%)	-	-	-	-	8.3
Hui et al. [8]	176	35%	4.0%	-	-	165 (94%)	26 months	Locoregional recurrence (%)	-	-	-	-	35.0
Fields et al. [11]	153	29%	100%	30	-	30 (20%)	41 months	Locoregional recurrence (%)	-	-	-	-	13.0
Veness et al. [5]	86	41%	18.3%	43	6	49 (57%)	31 months	Local and/or nodal relapse (%)	-	-	-	-	31.0
Fang et al. [12]	50	100%	52.00% (remainder cN+)	45	2	47 (94%)	18 months	2-year regional recurrence-free survival (%)	-	-	100	75	12.0
Mehrany et al. [13]	60	33%	100%	16	-	16 (27%)	SLNB (−) 7.3 months SLNB (+) 12 months	Local, regional, or distant recurrence (%)	-	-	-	-	33.0
Deneve et al. [14]	38	100%	0.0%	26	9	35 (92%)	25.1 months	Regional recurrence (%)/any recurrence (%)	-	-	-	11/34	-
Ma et al. [15]	962	100%	100%	356	-	356 (37%)	32.0 months	5-year overall survival (%)	-	-	50.9	-	50.9
Cass et al. [16]	80	32.5%	80%	71	8	79 (99%)	35 months	3-year local recurrence-free survival (%)	-	-	-	-	94
Broida et al. [17]	120	31%	91%	86	-	86 (72%)	48 months	5-year disease-specific survival (%)	88		89	40	82
Pottier et al. [18]	312	28.9%	37%	226	-	226 (72%)	-	Recurrence rate (%)	37.6		22.2	50.7	39.5
Strom et al. [19]	113	26.1%	61.1%	81	-	81 (72%)	27 months	3-year recurrence-free survival (%)	83.5		87.4	50.0	-

Case series of MCC reporting recurrence rates and including node-positive patients with use of adjuvant radiation therapy. Abbreviations: N = number, SLNB = sentinel lymph node biopsy, cN+ = clinically node-positive.